<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04495036</url>
  </required_header>
  <id_info>
    <org_study_id>Req-2019-00523; sp20Maul2</org_study_id>
    <nct_id>NCT04495036</nct_id>
  </id_info>
  <brief_title>Acceptance of Telemedicine in Dermatology Patients, Physicians and Medical Staff</brief_title>
  <official_title>Acceptance of Telemedicine in Dermatology Patients, Physicians and Medical Staff</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the current use and intention to use of teledermatology in Swiss&#xD;
      dermatology patients, dermatologists, other physicians and medical staff.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Telemedicine, the use of telecommunication and information technology to provide clinical&#xD;
      health care from a distance, has become an increasing role in basic medical care&#xD;
      internationally. Telemedicine is particularly suitable for skin diseases. In order to improve&#xD;
      the use of evidence-based telemedicine, the Swiss patients' preferences regarding&#xD;
      teledermatology versus face-to-face consultations and the patients' and physicians'&#xD;
      determinants of acceptance for teledermatology are investigated in this study. Dermatology&#xD;
      patients are asked to complete a newly-created 21-items-survey; Swiss dermatologists, other&#xD;
      physicians and medical staff on telemedicine will complete a similar newly-created,&#xD;
      23-items-questionnaire. A descriptive statistical analysis (e.g. gender, age, place of&#xD;
      residence (city or country), waiting time) will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>descriptive analysis: deviation in influencing factors for the acceptance of teledermatology</measure>
    <time_frame>at baseline</time_frame>
    <description>Assessment of the deviation in influencing factors for the acceptance of teledermatology (subjective disease perception versus objective assessment by physicians)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>descriptive analysis of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients</measure>
    <time_frame>at baseline</time_frame>
    <description>Comparison of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">683</enrollment>
  <condition>Dermatologic Disease</condition>
  <arm_group>
    <arm_group_label>dermatology patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>physicians and medical staff</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection (21-items-patient descriptive survey)</intervention_name>
    <description>Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:&#xD;
Demographic data of telemedicine users and non-users&#xD;
Subjective disease perception of the dermatology patients&#xD;
Use of internet, telemedicine and telemedicine insurance model&#xD;
Patients´ willingness for additional features of telemedicine&#xD;
Advantages and disadvantages telemedicine and face-to-face consultation&#xD;
Suitable fields of dermatology for telemedicine from the patient's perspective&#xD;
Recommended structure of telemedical services by users and non-users</description>
    <arm_group_label>dermatology patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection (23-items-physician descriptive survey)</intervention_name>
    <description>To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:&#xD;
Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)&#xD;
Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective</description>
    <arm_group_label>physicians and medical staff</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and the&#xD;
        University Hospitals Basel and Zürich and Dermatologists, other physicians and medical&#xD;
        staff of the Department of Dermatology of the Cantonal Hospital Aarau and the University&#xD;
        Hospitals Basel and Zürich.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and&#xD;
             the University Hospitals Basel and Zürich&#xD;
&#xD;
          -  dermatologists, other physicians and medical staff of the Department of Dermatology of&#xD;
             the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lara Valeska Maul, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Teledermatology</keyword>
  <keyword>Telemedicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04495036
org study id: Req-2019-00523; sp20Maul2
nct id: NCT04495036
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This study is to investigate the current use and intention to use of teledermatology in Swiss
      dermatology patients, dermatologists, other physicians and medical staff.
Telemedicine, the use of telecommunication and information technology to provide clinical
      health care from a distance, has become an increasing role in basic medical care
      internationally. Telemedicine is particularly suitable for skin diseases. In order to improve
      the use of evidence-based telemedicine, the Swiss patients' preferences regarding
      teledermatology versus face-to-face consultations and the patients' and physicians'
      determinants of acceptance for teledermatology are investigated in this study. Dermatology
      patients are asked to complete a newly-created 21-items-survey; Swiss dermatologists, other
      physicians and medical staff on telemedicine will complete a similar newly-created,
      23-items-questionnaire. A descriptive statistical analysis (e.g. gender, age, place of
      residence (city or country), waiting time) will be performed.
observational model: Cohort
time perspective: Prospective
measure: descriptive analysis: deviation in influencing factors for the acceptance of teledermatology
time frame: at baseline
description: Assessment of the deviation in influencing factors for the acceptance of teledermatology (subjective disease perception versus objective assessment by physicians)
measure: descriptive analysis of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients
time frame: at baseline
description: Comparison of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients
arm group label: dermatology patients
arm group label: physicians and medical staff
intervention type: Other
intervention name: data collection (21-items-patient descriptive survey)
description: Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:
Demographic data of telemedicine users and non-users
Subjective disease perception of the dermatology patients
Use of internet, telemedicine and telemedicine insurance model
Patients´ willingness for additional features of telemedicine
Advantages and disadvantages telemedicine and face-to-face consultation
Suitable fields of dermatology for telemedicine from the patient's perspective
Recommended structure of telemedical services by users and non-users
arm group label: dermatology patients
intervention type: Other
intervention name: data collection (23-items-physician descriptive survey)
description: To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:
Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)
Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective
arm group label: physicians and medical staff
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Lara Valeska Maul, Dr. med.
role: Principal Investigator
affiliation: Department of Dermatology, University Hospital Basel
facility: 
facility: 
facility: 
country: Switzerland
responsible party type: Sponsor
mesh term: Skin Diseases